<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840058</url>
  </required_header>
  <id_info>
    <org_study_id>API/2015/58</org_study_id>
    <nct_id>NCT02840058</nct_id>
  </id_info>
  <brief_title>Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1</brief_title>
  <acronym>ITHER</acronym>
  <official_title>Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent scientific advances have shown the important role of immune system against cancer.&#xD;
      Today, many immunological biotherapy like anti-PD1/PDL-1 are available in cancer treatment&#xD;
      and generate durable clinical responses in some patients. The development of tools for&#xD;
      monitoring anti-tumor immune responses dynamically is a major challenge to predict the&#xD;
      effectiveness of immunotherapies anti-PD-1 and anti-PDL-1.&#xD;
&#xD;
      Thus, the objective of our study is to analyse the interest of the monitoring of&#xD;
      anti-telomerase T helper 1 (TH1) responses in predicting the efficacy of immunotherapy, using&#xD;
      an immunoassay developed by our group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti-telomerase specific Th1 responses</measure>
    <time_frame>up to 12 months after the initiation of anti-PD1/PDL1 therapy</time_frame>
    <description>measured by ELISPOT assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 12 months after the initiation of anti-PD1/PDL1 therapy</time_frame>
    <description>according to RECIST v1.1 criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Biological samples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples will be realized specifically to the study at inclusion (baseline before starting anti PD1/PDL1 treatment), and then 1 month, 3 months and 12 months after initiation of anti-PD1/PDL1 treatment.&#xD;
Peripheral blood mononuclear cells (PBMC) and plasma will be collected.&#xD;
Available tumor tissues will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological samples</intervention_name>
    <description>blood and tumor tissue samples</description>
    <arm_group_label>Biological samples</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti PD1/PDL1 treatment</intervention_name>
    <arm_group_label>Biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with metastatic or locally advanced cancer candidate to anti-PD1/PDL1&#xD;
             immunotherapy&#xD;
&#xD;
          -  Performance status 0, 1 or 2 on the ECOG scale&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under chronic treatment with systemic corticoids or other immunosuppressive&#xD;
             drugs (prednisone or prednisolone ≤ 10 mg/day is allowed)&#xD;
&#xD;
          -  Prior history of other malignancy except for: basal cell carcinoma of the skin,&#xD;
             cervical intra-epithelial neoplasia and other cancer curatively treated with no&#xD;
             evidence of disease for at least 5 years&#xD;
&#xD;
          -  Active autoimmune diseases, HIV, hepatitis C or B virus&#xD;
&#xD;
          -  Patients with any medical or psychiatric condition or disease,&#xD;
&#xD;
          -  Patients under guardianship, curatorship or under the protection of justice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura MANSI, Dr</last_name>
    <email>mansi.laura@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe BORG, Pr</last_name>
    <email>christophe.borg@efs.sante.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura MANSI, Dr</last_name>
      <email>lmansi@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

